2021 Year in Review - Gastrointestinal Cancer

Clinical study results indicate pembrolizumab monotherapy improves response rate in patients with advanced refractory esophageal cancer. Read More ›

Avelumab maintenance therapy conveys no overall survival difference over the use of continued chemotherapy in patients with advanced GEJC or gastric cancer. Read More ›

The dose-escalation phase of the EMERGE clinical trial results show that 200 mg domatinostat twice daily is safe and efficacious. Read More ›

No survival advantage was observed with durvalumab use in the PLATFORM clinical trial, but a patient subgroup was observed to have a radiological response. Read More ›

CheckMate-577 clinical trial results show nivolumab adjuvant therapy increases disease-free survival over placebo in patients with gastroesophageal junction (GEJ) cancer or esophageal cancer. Read More ›

Second-line or later nivolumab monotherapy yields no clear evidence of efficacy advantage for patients with advanced esophageal cancer. Read More ›

Recently released positive findings from the LEAP-005 trial of lenvatinib plus pembrolizumab in the treatment of previously treated gastric cancer leads to cohort expansion. Read More ›

Results from the CheckMate-648 study demonstrate that nivolumab added to either ipilimumab or chemotherapy improves overall survival in patients with advanced esophageal squamous-cell carcinoma. Read More ›

Nivolumab combined with chemotherapy had improved survival outcomes and an acceptable safety profile in patients with advanced gastric/esophageal cancer, according to CheckMate-649 study results. Read More ›

Page 3 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: